Administration of recombinant tumor necrosis factor to rats bearing the Dunning R3327 MAT-LyLu prostatic adenocarcinoma.
Copenhagen X Fischer F1 rats bearing palpable Dunning R3327 MAT-LyLu prostatic adenocarcinomas were treated by intraperitoneal (i.p.) or intratumor (i.t.) injection with either human serum albumin alone or in combination with recombinant tumor necrosis factor (rTNF). At intervals tumors were measured and survivals noted. A maximum tolerable dose and least toxic route of administration was then determined. Those treated i.t. with rTNF survived significantly longer and ultimately developed significantly smaller tumors than untreated controls. Those administered rTNF by the i.p. route had less significant increases in survival with intermediate final tumor sizes.
Shaw
M W
MW
Division of Urology, Cook County Hospital, Chicago, Ill.
Guinan
P D
PD
Dubin
A
A
McKiel
C F
CF
Rubenstein
M
M
D000818:Animals; D005260:Female; D007267:Injections; D007274:Injections, Intraperitoneal; D008297:Male; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000627:therapeutic use*
D014409:Tumor Necrosis Factor-alpha